Showing results (11-20 of 65) with videos related to
Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|May 21, 2016
Can immunostimulatory agents enhance the abscopal effect of radiotherapy?Antonin Levy, Cyrus Chargari, Aurelien Marabelle, et al.Cancer Discovery|April 3, 2021
Overcoming Resistance to Tumor-Targeted and Immune-Targeted TherapiesMihaela Aldea, Fabrice Andre, Aurelien Marabelle, et al.ERJ Open Research|April 28, 2020
A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancerClémence Legoupil, Didier Debieuvre, Aurelien Marabelle, et al.Nature Reviews. Clinical Oncology|July 9, 2020
Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigmCaroline Robert, Aurelien Marabelle, Hugo Herrscher, et al.Annual Review of Medicine|November 13, 2025
Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody DevelopmentMariela Navarrete, Cristobal Costoya, Felipe Galvez-Cancino, et al.Journal for Immunotherapy of Cancer|January 6, 2025
Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinomaChristophe Maritaz, David Combarel, Cécile Dalban, et al.Oncoimmunology|July 29, 2016
Tetraspanin CD81, a modulator of immune suppression in cancer and metastasisFelipe Vences-Catalán, Ranjani Rajapaksa, Minu K Srivastava, et al.Cancer Research|September 3, 2015
Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cellsFelipe Vences-Catalán, Ranjani Rajapaksa, Minu K Srivastava, et al.Journal for Immunotherapy of Cancer|February 28, 2020
Repurposing infectious disease vaccines for intratumoral immunotherapyIgnacio Melero, Maria Gato, Tala Shekarian, et al.Journal for Immunotherapy of Cancer|September 24, 2025
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockadeRomain Guitton, Ariane Laparra, Noemie Chanson, et al.Pageof 7